CD274 and neoplasm: In the forest plot analysis, the centrally assessed PFS was more favorable with nivolumab plus chemotherapy (95% CIs did not cross 1) in most subgroups, including patients with tumor cell PD-L1 expression < 1% or indeterminate (Fig. 1c).